Introduction
with endogenous gene expression. 7 Utilizing a bacterial The expression of most mammalian genes is intricately tetracycline-responsive operon element, Gossen et al regulated in vivo in response to a wide range of stimuli, developed an interesting model for controlling gene including physical (pressure, temperature, light), electriexpression with a tetracycline-controlled transactivator cal (eg motor and sensory neuron signal transmission) as (tTA and rtTA). 8, 9 No et al recently reported a threewell as biochemical (ions, nucleotides, neurotransmitters, component system consisting of a chimeric GAL4-VP16-steroids and peptides) in nature. While the mechanism ecdysone receptor, its partner retinoid X receptor (RXR), of transcriptional regulation of gene expression has been and a target gene; they demonstrated its application in extensively studied, 1 progress on achieving target gene activating reporter gene expression in an ecdysoneregulation in mammalian cells, without interfering with dependent manner. 10 endogenous gene expression, has been limited. CurPreviously we have reported a novel RU486-inducible rently, most strategies for target gene activation or system for controlling target gene expression. 11 This repression are performed in a constitutive manner. Such inducible system consists of a regulator and a target gene. uncontrolled regulation of gene expression is not ideal
The regulator is a chimeric RU486-inducible transcripphysiologically, and can even be deleterious to cell tional activator composed of a VP16 transcriptional actigrowth and differentiation.
vation domain in the N-terminus followed by a yeast Several inducible systems have been employed for con-GAL4 DNA binding domain and a mutated human protrolling target gene expression. These inducible agents gesterone receptor (hPR) ligand binding domain (LBD). include heavy metal ions, 2 heat shock, 3 isopropyl ␤-dThis mutated PR, containing a 42 amino acid deletion in thiogalactoside (␤-gal), 4 and steroid hormones such as the C-terminus (⌬C42) of the LBD, does not bind to proestrogen 5 and glucocorticoids. 6 However, many of these gesterone, but binds the progesterone antagonist RU486 (mifepristone) and activates transcription. 12 The advantage of using the yeast GAL4 DNA binding domain is its specificity, since this chimeric regulator will only recog-433 binding) sequence but not the endogenous mammalian
To understand whether additional activation domains of the same type would also increase the activation genes. Moreover, this system is only activated in the presence of an exogenous compound, RU486, but not by any potential of the chimeric regulator, we constructed GLVP × 2 with two copies of VP16 activation domain at endogenous molecules present in the mammalian tissues and organs. Furthermore, the regulator GLVP was actithe N-terminus ( Figure 1a ). As shown in Figure 1c , further addition of the same type of transactivation vated by a very low concentration (0.1-1 nm) of a synthetic and orally active antiprogestin RU486. We have domain (VP16) did not increase the activation potential of the regulator. demonstrated previously the successful use of this system both in vitro and ex vivo 11 with different target gene constructs harboring either the chloramphenicol acetylExtension of the ligand binding domain of hPR further improves the responsiveness of GLVP to RU48 transferase or the tyrosine hydroxylase gene.
While the original GLVP can efficiently activate target The original chimeric regulator GLVP contains a Cterminally truncated hPR-LBD at amino acid (aa) position gene expression containing stronger promoters such as the thymidine kinase (tk) promoter, its activity on a mini-891, which disrupted the activation function (AF2) as well as the dimerization ability of the hPR. We asked mal TATA promoter is limited. To enhance further the transcriptional activity of GLVP, we report here the genwhether an increase in the length of hPR-LBD in the GLVP might enhance its transcriptional activity in eration of a more potent RU486-inducible gene regulator. Most importantly, this new gene regulator responds to response to the antiprogestin RU486. For this purpose, a series of deletion mutants which extend the C-terminus RU486 at a concentration even lower than that used by the original GLVP. At this concentration, RU486 does not of the LBD from aa 879 to aa 928 were generated ( Figure  2a ). These mutants were examined for their ability to conhave any anti-progesterone or anti-glucocorticoid activity. The inducible system has been used successfully fer stronger RU486, but not progesterone, inducible activity in transient cotransfection assay with a 17 × 4-to produce secreted NGF from a reporter gene in an RU486 dependent manner to induce neurite outgrowth TATA-CAT reporter construct. By lengthening the C-terminal ligand binding domain from 879 to 914 (Figure 2a ), in co-cultured PC12 cells (of rat adrenal pheochromocytoma). We also demonstrate that this RU486-controlwe observed a gradual increase in RU486 induced activation of target gene expression (Figure 2b ). Importantly, lable ligand binding domain can be converted to an inducible repressor for shutting down target gene these mutants responded specifically to RU486, but not to the progesterone agonist R5020. Further extension of expression. Collectively, these studies demonstrate that individual domains within a chimeric fusion protein the C-terminal LBD beyond aa 914 resulted in a decrease of GLVP response to RU486 (Figure 2b ). influence each other's function in a position-dependent context.
Location of the transcriptional activation domain VP16 within the chimeric regulator affects its transactivation
Results potential
The original chimeric regulator GLVP contained the VP16 transcriptional activation domain located at the NRole of additional activation domains in the chimeric regulator terminus of the molecule. To address the possibility whether positioning of the VP16 activation domain Several different functional domains have been characterized in transcription factors; they can be either acidic within the chimeric molecule would affect its transcription activation potential, we constructed a series of chim-(VP16, GAL4), glutamine-rich (SP1, Oct-1, Oct2A), proline-rich (Oct3/4), or serine-and threonine-rich eric regulators with the VP16 activation domain located at the C-terminus. As illustrated in Figure 3 , the regulator (Pit1). 13 It is known that different types of transcriptional activation domains interact with different coactivators of with a C-terminally located VP16 is more potent than its N-terminal counterpart (compare GLVP and GL 891 VP CЈ in the general transcriptional machinery. When different activation domains are fused together in a transactivator, Figure 3a and GL 914 VP and GL 914 VP CЈ in Figure 3b ). In addition, extension of the C-terminal LBD from aa 879 to they can synergize with each other to increase its transcriptional potential. Recently, Schaffner and colleagues 14 aa 914 further increased transactivational activity of the regulator in this C-terminally located VP16 chimera demonstrated that insertion of either a poly-glutamine (poly-Q) or poly-proline (poly-P) stretch within the (compare GL 879 VP CЈ with GL 914 VP CЈ in Figure 3a) . Thus, extension of the LBD to aa 914 further enhances the GAL4-VP16 enhances the activation of GAL4-VP16. In order to increase the potency of the GLVP regulator, we RU486-dependent transactivation, irrespective of whether VP16 is located in the N-or C-terminus, suggestinserted varying lengths of poly-Q stretches encoded by the triplet repeats (CAG)n, into the N-terminus of the ing the existence of a weak dimerization and activation function between aa 879 and 914 of the PR-LBD. By trans-GLVP regulator (Figure 1a ). Transactivation analysis of the various sizes of poly-Q insertions in the GLVP indiferring the VP16 activation domain from the N-terminus to the C-terminus, we generated a much more potent cate that addition of 10-34Q increases transcriptional activity of the regulator on the reporter gene (17 × 4-transactivator GL 914 VP CЈ . In order to exclude the possibility that this significant difference in the capacity for TATA-hGH), while further extension of poly-Q from a 66 Q oligomer to a 132 Q oligomer results in decreased gene activation was not due to different protein expression levels of the two chimeric regulators, we peractivation of the target gene (Figure 1b) . These experiments demonstrated that a combination of different types formed Western blot analysis of extracts from HeLa cells transiently transfected with either GL 914 VP or GL 914 VP CЈ of functional domains of appropriate strength further improves the activation potential of the GLVP chimeric (duplicates) and confirmed that the two regulator proteins are expressed at a similar level (Figure 3c , compare regulator. 40 lanes 2 and 3 with lanes 4 and 5). Together, these results chimeric regulator GLVP to activate target gene expression at a substantially lower concentration of suggested that through modification of the PR-LBD within the chimeric regulator we could further improve RU486. We examined the optimal concentration of RU486 for these two transcriptional activators GL 914 VP CЈ and its response to a ligand by approximately one order of magnitude.
Figure 1 Effect of additional transcriptional activation domain on GLVP activity. (a) Diagrams of GLVP and its derivatives containing an additional transactivation domain. In GLVP-nQ, a poly-glutamine (n-oligomer) stretch was fused directly to the N-terminal part of the GLVP. GLVP × 2 has tandem copies of VP16 activation domain (ac 411-487) fused together at the N-terminus. The reporter plasmid, 17 × 4-TATA-hGH,
GL 914 VP. As shown in Figure 4 , GL 914 VP activity occurred at an RU486 concentration of 0.1 nm and reached a maximal level at 1 nm. The result is similar to The new regulator GL914VP CЈ activates target gene expression potently at a lower concentration of RU486
what we have observed previously in a stable cell line harboring the GLVP and reporter 17 × 4-tk-TH (tyrosine Since RU486 has been known to act as an antagonist of progesterone and glucocorticoid when used at a high hydroxylase). 11 In contrast, GL 914 VP CЈ increased reporter gene expression at an RU486 concentration 10-fold lower concentration (100 nm), it would be desirable for the
Figure 2 Extension of the ligand binding domain enhances RU486-inducible transcriptional activation. (a) Diagram of the original chimeric GLVP and its C-terminally extended derivatives. VP16 activation domain contains aa 411-489 of the HSV VP16, the GAL4 DNA binding domain was derived from residue 1 to 93. Different amino acid segments of the human progesterone receptor (hPR) ligand binding domain (LBD) were used in the chimeric protein. (b) Various C-terminal truncations of progesterone receptor ligand binding domain affect the transactivation potential of chimeric regulator. Transient transfection assay shows the activity of various GLVP derivatives on activation of target gene 17 × 4-TATA-CAT. HeLa cells were transfected with 4 g of chimeric regulators (driven by RSV promoter) as indicated and 10 g of reporter 17 × 4-TATA-CAT. After transfection, cells were incubated with either 10 nm RU486 (RU) or 10 nm progesterone agonist R5020 (P). Ethanol (85%) was used as vehicle control (−).
(0.01 nm) than that of GL 914 VP. Thus, the modified KRAB located in the C-terminus (GL 914 KRAB). This observation is similar to what we have observed pre-GL 914 VP CЈ is not only more potent but also activates the reporter gene at a lower concentration of ligand as comviously with the positioning of the VP16 activation domain. pared with GL 914 VP. This newly discovered character of GL 914 VP CЈ is important for its use in inducible target gene expression, since it would allow the use of a concenInducible neurite outgrowth in PC12 cells with regulated expression of nerve growth factor tration which has no anti-progesterone or anti-glucocorticoid activity. This represents a significant advantage To demonstrate the use of the inducible system in a biological situation, we designed a regulatable expression when the inducible system is applied in in vivo situations, as exemplified by transgenic mice and potentially by model for nerve growth factor (NGF). NGF has been shown to stimulate neurite (axon) outgrowth of PC12 gene therapy. cells (from rat adrenal pheochromocytoma) when added to the cell culture medium. 18 We have established a stable Inducible repression of target gene expression To explore the possibility of converting a transactivator rat fibroblast cell line (C4FRNGF) that possesses both regulator GL 914 VP CЈ and reporter 17 × 4-TATA-NGF. GLVP to a regulatable repressor, we replaced the VP16 activation domain with a repression domain, the These cells were grown in the presence or absence of RU486 (10 nm) for 2 days and the conditioned medium Krü ppel-associated box-A (KRAB), from the zinc finger protein Kid-1. Kid-1 was identified as a kidney-specific was collected and assayed for NGF-stimulated neurite outgrowth of PC12 cells. When conditioned medium transcription factor and was shown to be regulated during renal ontogeny and injury. 16, 17 The KRAB domain (aa (from C4FRNGF cells treated with RU486) was added to PC12 cells, we observed strong neurite outgrowth from 1-70) was inserted in either the N-or C-terminus of GL 914 ( Figure 5a ) and inducible repression by RU486 was ana-PC12 cells after 48 h of incubation ( Figure 6C and D). Little if any neurite outgrowth was observed in PC12 lyzed in cotransfection experiments using HeLa cells. The reporter plasmids 17 × 4-tk-CAT (with the thymidine kincells incubated with the conditioned medium that was collected from stable cells treated with vehicle only (85% ase promoter) and 17 × 5-SV-CAT (containing the SV40 enhancer) were selected in order to study the repression ethanol) ( Figure 6 A and B ). These results demonstrate that the inducible system can be used to study a partiof basal promoter and enhancer-mediated transcriptional activity, respectively. Both reporters contain multiple cular biological phenomenon in a controllable fashion. copies of the GAL4 binding site (17-mer UAS sequence) and exhibit constitutive basal expression from either a tk Discussion promoter or SV40 enhancer by themselves. As shown in Figure 5b , the chimeric regulator GL 914 KRAB, with the Transcriptional regulation of gene expression has been intensively studied over the past decade. 1, 19, 20 It is gener-KRAB repression domain inserted in the C-terminus, strongly repressed expression (six-to eight-fold) of both ally believed that transcription factors selectively bind to their recognition sequences on DNA (promoters and reporters in an RU486-dependent manner. However, the N-terminally located KRAB repression domain enhancers) and directly interact with the TBP-associated factors (TAFs), coactivators, or corepressors to activate or (KRABGL 914 ) did not repress target gene expression in the presence of RU486 to the degree of that achieved with repress transcriptional activity. Nuclear hormone recep- tors, such as steroid, thyroid, retinoid and orphan recepaddition of this short stretch of 23 aa increases the PR-LBD's dimerization potential and subsequent binding to tors, are a unique class of inducible transcription factors that can modulate their respective target genes in its response element. During the course of this study, we also discovered that further extension of the hPR-LBD response to their cognate ligands. Recently, we and others have identified several coactivators (SRC-1), 21 from residue 917 to 928 results in a decrease of transactivation, suggesting that this region may serve as a repressor CBP, 22 and corepressors (N-CoR, SMART) 23,24 that mediate nuclear hormone receptor activation of target interacting domain. In fact, when this 12 aa stretch was ligated to the GAL4 DNA binding domain, it was sufgenes. These studies suggest that multiple protein factors are involved in the complex process of transcriptional ficient to confer transcriptional repression of a target gene, suggesting that these 12 aa might interact with a regulation of gene expression.
To understand further this complex process of gene yet unidentified cellular co-repressor. 25 Many chimeric proteins have been constructed in regulation, we have utilized an inducible chimeric regulator to study: (1) activates target gene expression containing a minimal promoter at an RU486 concentration 10-fold lower than its N-terminally located VP16 counterpart, GL 914 VP. At this concentration, RU486 is expected to have no interIn all, mutational studies revealed that the chimeric regulator GL 914 VP CЈ is about eight to 10 times more potent ference with endogenous gene expression. Therefore, this new inducible system will afford an improved margin of than our originally described regulator GLVP and responds at a lower ligand concentration. Our results also safety over our previously reported GLVP and further contribute to its application for gene regulation in vivo.
demonstrated that within a chimeric protein, individual Expanded regions of triplet CAG repeats have been isolated from Kox1 zinc finger protein, which shares extensively homology with that of Kid-1, interacts with a implicated in several neurodegenerative diseases such as Huntington's, Kennedy's, dentatorubral-pallidoluysian 110 kDa adaptor protein termed SMP1 (silencingmediating protein 1). The characteristics and mechanism atrophy (DRPLA), and hereditary spinocerebellar ataxias (SCA1).
Figure 5 Inducible repression of target gene expression. (a) Diagram of inducible repressor and reporter constructs. Kid-1 KRAB domain containing amino acid residues 1-70 was fused to the N-or C-terminus of the GAL4-PRLBD (640-914) chimera. (b) CAT assay demonstrating inducible repression of target gene expression in the presence of RU486. HeLa cells were cotransfected with 4 g of expression plasmid containing the inducible repressor constructs and 10 g of reporter plasmid. pCEP4 parental vector was used as the control. After transfection, cells were incubated with either 10 nm of RU486 (+) or vehicle control (−). Numbers indicate the percentage of acetylated chloramphenicol (% conversion) and fold repression in the presence
27-29 Recently, several groups have isolated proof this adaptor protein have yet to be determined. Using the newly modified GL 914 VP CЈ , we have successteins responsible for the above mentioned neurodegenerative diseases and confirmed that they indeed contain fully achieved regulation of neurite outgrowth in PC12 cells via RU486 controllable expression of NGF. Our studlong poly-glutamine (Q) stretches encoded by the expanded CAG repeats. [30] [31] [32] To understand further the ies show that this novel inducible system can be employed to analyze biological function in a temporal role of poly-Q stretches in transcriptional regulation, we inserted various lengths of poly-Q in the N-terminus of manner. For example, the role of a growth factor could be assessed at a particular stage of development and the GLVP. Our results demonstrated that addition of a 10-34 oligomer of poly-Q results in synergistic transcriptional sequential relationship of in vivo cell death and proliferation could be delineated in a manner not possible with activation, while expanded CAG triplet repeats beyond 66 oligomeric glutamines do not increase further the constitutive expression of the test gene.
Recently, we have successfully demonstrated tissuetransactivation potential of chimeric regulator GLVP. These observations suggest that structural and conforspecific regulation of gene expression in transgenic mice utilizing this inducible system. 39 We also foresee the use mational changes might be involved in proteins encoded by the expanded CAG triplet repeat as compared with of our RU486 inducible regulator to create an inducible gene knockout (either temporal and/or spatial) in transthe regular length poly-Q which is encoded by 10-30 repeats of CAG in normal protein. These results suggest genic mice which could circumvent an embryonic lethality resulting from the use of current gene knockout techthat a neurological disease with expanded CAG repeats (Ͼ40 mer) may not be due to aberrant high transcripniques. We envision that combinatorial inclusion of other inducible systems such as the tetracycline or ecdysone tional potential but rather due to an influence on other aspects of cell function. 33 system with the RU486 inducible system might allow biologists one day to modulate complex biological pro-A transcription factor can either activate or repress gene expression depending on the promoter/enhancer cesses which involve multiple levels of control. context of its particular target DNA and the coregulator proteins with which it interacts. 34 For example, in the
Materials and methods
absence of thyroid hormone (T3), the thyroid hormone receptor (TR) normally binds to its recognition sequence Plasmid constructs on DNA and represses target gene activation through interactions with corepressors (Refs 24, 35 and H Shibata, SY Tsai, M-J Tsai, BW O'Malley (unpublished data)). In
Construction of poly-glutamine stretch insertion into GLVP: The poly-glutamine stretch containing multiple the presence of T3, the corepressor is released from the receptor and coactivators are recruited to enhance gene repeats of CAG was constructed by a method developed by Seipel et al 15 utilizing multimerization of DNA fragexpression. Many transcription factors, such as p53, WT-1, YY1, Rel, can also act as dual activators and repressors ment (BsaI and BbsI digested) coding glutamine repeats leading to poly-Q n . Plasmid pBluescript-KS(II) was depending on the DNA template and protein cofactors with which they interact. The Drosophila zinc finger trandigested with Acc65I and SacI, the linearized vector was gel purified and ligated with the annealed oligonucleoscription factor, Krü ppel, is encoded by a gap gene and is essential for organogenesis during later stages of the tide pair R3/R4 to create plasmid pPAP. respectively. The insert was confirmed by restriction digestion and amplified with two sets of primers for insertion into the N-or C-terminus of GL 914 , respectively. For the KRAB sequencing. The plasmid with 10Q insert (pPAP-10Q) was digested with BsaI and BbsI (New England Biolab, domain to be inserted at the N-terminus of the fusion protein, the Kid-1 cDNA was amplified with a set of priBeverly, MA, USA) overnight and precipitated. Onetenth of the precipitated DNA (containing both vector mers as follows: Kid3: 5′-CGACAGATCTGGCTCCTGAG CAAAGAGAA-3′, Kid4: 5′-CCAGGGATCCTCTCCTTGC and fragment) was re-ligated to create plasmid pPAP-18Q. Each ligation step results in pAP-2(n-1)Q from the TGCAA-3′. The PCR products were digested with BglII and BamHI and subcloned into pRSV-GL 891 to create previous vector pPAP-nQ. In this way various expansions of poly-Q were achieved and the resulting plasmids pRSV-KRABGL 891 . The KpnI-SalI fragment of KRABGL 891 was then purified and subcloned into KpnI-SalI sites in pPAP-34Q, pPAP-66Q and pPAP132Q were created and confirmed by sequencing. The BglII and BamHI fragments pRSV-GL 914 VP to create pRSV-KRABGL 914 . The entire KRABGL 914 fragment (KpnI-BamHI) was then inserted (coding for poly-Q stretch) from these plasmids were purified and cloned into the BglII site of pRSV-GLVP to into the KpnI and BamHI-digested pCEP4 generating pCEP4-KRABGL 914 . For C-terminally located KRAB generate GLVP with various poly-Q inserts at the N-terminus. These GLVP-nQ were reinserted into the pCEP4 domain, the Kid-1 gene was amplified with the following set of primers: Kid1: 5′-TCTAGTCGACGATGGCTCCTG expression vector (containing CMV immediate-early gene enhancer/promoter) creating pCEP4-GLVP-nQ.
AGCAAAGAGAAG-3′, Kid2: 5′-CCAGGGATCCTATCC TTGCTGCAACAG. The primer Kid2 also contains a termination codon (TAG) after aa 70. The PCR products Chimeric fusion protein with various C-terminus deletions: To construct GLVP chimeras with various C-terminal were digested with SalI and BamHI and purified using QIAEX II gel extraction kit (Qiagen). The HindIII and SalI deletions of the human progesterone receptor ligand binding domain, the HindIII to BamHI fragment containfragment (317 bp) from pBS-GL 914 VP CЈ , was isolated as was the vector fragment of pCEP4-GL 914 VP CЈ digested ing these various deletions in pRSV-hPR plasmids 25 was gel purified with QIAEX II gel extraction kit (Qiagen, with HindIII and BamHI. These three piece fragments were ligated to create pCEP4-GL 914 KRAB. Chatworth, CA, USA). The purified fragments were subcloned into HindIII and BamHI sites of pRSV-GLVP 11 replacing the aa region 610-891 of the GLVP.
Transient transfection, CAT assay, hGH assay and Western blot HeLa and CV1 cells were transfected with the described GLVP CЈ chimeras with VP16 activation at the C-terminus: We used two-step clonings to move VP16 activation to amount of DNA using the polybrene-mediated Ca 2 PO 4 precipitation method and CAT assay was performed and the C-terminus of the chimeric fusion protein. First, the hPR-LBD region (from aa 800 to various C-termini) was quantified as described previously. 11 HepG2 cells (10 6 ) were grown in DMEM with 10% fetal bovine serum and amplified using 5′ primer (5′-TATGCCTTACCATGT GGC-3′) with a different 3′ primer as a pair and digested 1 × penicillin-streptomycin-glutamine (GIBCO-BRL, Gaithersburg, MD, USA) and transfected with the polywith HindIII to SalI to prepare the fragment for ligation. For a different position of amino acid truncation, the 3′ brene-mediated Ca 2 PO 4 precipitation method. Aliquots of the cell culture media were taken at different time primers incorporating the SalI site are: P3S-879: 5′-TTGG TCGACAAGATCATGCATTATC-3′; P3S-891: 5′-TTGTC intervals and hGH production was measured using the hGH clinical assay kit (Nichols Institute Diagnostics, San GACCCGCAGTACAGATGAAGTTG-3′, and P3S-914: 5′-TTGGTCGACCCAGCAATAACTTCAGACATC-3′. The Juan Capistrano, CA, USA) according to the manufacturer's instructions. For Western blot analysis, protein DNA fragment containing the VP16 activation domain (aa 411-490) was isolated from pMSV-VP16-⌬3′-␤58N′ extracts (20 g) were prepared from transiently transfected HeLa cells, separated on SDS polyacrylamide gel (from A Friedman, Johns Hopkins Oncology Center, Baltimore, MD, USA) with SalI and BamHI. The digested and trans-blotted on to nylon membrane as previously described. The blot was probed with anti-GAL4-DBD (aa PCR fragment and VP16 activation were ligated together into the HindIII and BamHI sites of expression vector 1-147) monoclonal antibody (Clontech, Palo Alto, CA, USA) and developed with an ECL kit (Amersham, pCEP4 (Invitrogen, San Diego, CA, USA). The ligated vector pCEP4-PV (LBD 810-879 and VP16), -C3 (LBD Arlington Heights, IL, USA). 810-891 and VP16), -C2 (LBD 810-914 and VP16), respectively, now contain C-terminal fragments of hPR-LBD Stable cell line generation and neurite outgrowth assay Rat FR cells, derived from rat fetal skin cells (CRL 1213; from the HindIII site (amino 810) to various truncations of LBD fused 3′ to the VP16 activation domain with American Type Culture Collection, Rockville, MD, USA) were transfected with pCEP4-GLVP 914 VP CЈ by the Ca 2 PO 4 BamHI after the termination codon of VP16. We then replaced the HindIII-BamHI fragment from pGL (in pAB method as described previously. 11 Cells were grown in DMEM with 10% fetal bovine serum and selected with vector) with PV, C3, and C2 fragments, respectively, to yield pGL 879 VP CЈ , pGL 891 VP CЈ , and pGL 914 VP CЈ . These 50 g/ml hygromycin-B (Boehringer Mannheim, Indianapolis, IN, USA). After 2-3 weeks, colonies were picked chimeric fusion proteins were then subcloned into Acc65I and BamHI sites of pCEP4 expression vector and were and subsequently expanded. Each clone was then transi-
